Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab, CAPOX, Bevacizumab, and Radiotherapy in Unresectable MSS Metastatic Colorectal Cancer
NCT07512674Phase 2Active, not recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Feb 2026
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, bevacizumab, capecitabine, oxaliplatin in colorectal cancer (CRC), sponsored by Sir Run-Run Shaw Hospital. Started Feb 2026; status: active, not recruiting.
02
Drugs
tislelizumabbevacizumabcapecitabineoxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07512674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07512674.